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SUMMARY 
The syncytiotrophoblast (ST) is one of the major components of the human placenta as it is 
involved in feto-maternal exchanges and the secretion of pregnancy-specific hormones. The 
aim of this study was to elucidate the formation and function of the ST in trisomy 21 (Down 
syndrome). We first used the in vitro model of cytotrophoblast differentiation into ST. 
Cytotrophoblasts were isolated from 15 trisomy 21-affected placentas (12-35 weeks of 
gestation) and 10 gestational age-matched control placentas. In vitro cytotrophoblasts isolated 
from normal placenta fused to form the ST. This was associated with an increase in the 
transcript levels and the secretion of human chorionic gonadotropin (hCG), human placental 
lactogen (hPL), placental growth hormone (PGH) and leptin.  In trisomy 21-affected 
placentas, we observed a defect (or a delay) in ST formation and a dramatic decrease in the 
synthesis and secretion of these hormones as compared to cultured cells isolated from control 
age-matched placentas. These results were confirmed by a significant (p<0.001) decrease in 
gene expression in total homogenates of trisomy 21-affected placentas as compared to 
control. These results will be of help in understanding the maternal hormonal markers of fetal 
trisomy 21 and the consequences of placental defects for fetal development. 
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INTRODUCTION 
 
 Trisomy of chromosome 21 (T21), which causes the phenotype known as Down 
syndrome, is the major known genetic cause of mental retardation and is found in around 
1:800 live births. Screening strategies to identify women at increased risk of bearing a T21-
fetus are based on maternal age, ultrasound signs (1, 2) or maternal serum markers (3-6). 
Some of these markers, such as hCG (4-6), are of placental origin. It is not known why 
maternal serum hCG is elevated in T21- affected pregnancies.  
 In human placenta, the syncytiotrophoblast, which forms the outer layer of the 
chorionic villi, is an active endocrine unit and secretes its hormonal products into the 
maternal circulation. Some of these polypeptide hormones are specific to pregnancy, such as 
human chorionic gonadotropin (hCG), human placental lactogen (hPL) and placental growth 
hormone (PGH) (7-9) and can be used as markers of syncytium formation.  The 
syncytiotrophoblast arises in vitro  (10, 11) and in vivo  (12) from differentiation of villous 
cytotrophoblasts. These cells aggregate and fuse to form multinucleated syncytiotrophoblasts. 
The morphological and functional differentiation of cytotrophoblasts into 
syncytiotrophoblasts can be induced or inhibited by  different factors such as cyclic AMP 
(13), growth factors like EGF (14) and TGFβ (15), polypeptide or steroid hormones such as 
hCG (16, 17) and dexamethasone (18), and oxygen tension (19, 20). 
 Despite the fact that some maternal serum markers of fetal T21 are of placental origin, 
little is known of placental defects in Down syndrome. Therefore, the aim of this work was to 
study trophoblast differentiation and endocrine functions in Down syndrome. 
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METHODS 
 
Placental tissue collection. French law allows termination of pregnancy with no gestational 
age limit when severe fetal abnormalities are observed. Samples of placental tissues were 
collected at the time of termination of pregnancy at 12-35 weeks of gestation (expressed in 
weeks of amenorrhea) in T21-affected pregnancies and gestational age-matched control cases. 
Details of history of all T21 and control cases are given in Table I. Gestational age was 
confirmed by ultrasound measurement of crown-rump length at 8-12 weeks of gestation. Fetal 
Down syndrome was diagnosed by karyotyping of amniotic fluid cells, chorionic villi or fetal 
blood cells. We checked that placental tissue was T21-affected by determination of DNA 
polymorphism markers (21). In no case was T21 due to translocation and no mosaicism was 
observed. Termination of pregnancy was performed in control cases affected by severe 
bilateral or low obstructive uropathy or major cardiac abnormalities. Fetal karyotype was 
normal in all controls. Placental samples were used for cytotrophoblast isolation or 
immediately frozen in liquid nitrogen. 
 
RNA isolation and analysis. Total RNA was extracted from frozen placental samples by 
means of the single-step guanidinium-phenol-chloroform method described by Chomczynski 
and Sacchi (22) and from cultured cells following the procedure of Qiagen (Courtabeuf, 
France). Total RNA concentration was determined at 260 nm and its integrity was monitored 
by 1% agarose gel electrophoresis. Relative mRNA levels of the different genes were 
measured with the TaqMan5’ nuclease fluorogenic quantitative PCR assay essentially as 
previously described (23). The nucleotide sequences of the primers and probes are listed in 
table II. Each sample was analyzed in duplicate and a calibration curve was run in parallel for 
each analysis. The level of transcripts of the constitutive housekeeping gene product 
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cyclophilin A was quantitatively measured in each sample to control for sample-to-sample 
differences in RNA concentration and quality. The PCR data are thus reported as the number 
of transcripts per number of cyclophilin A molecules. 
Cell culture. Villous tissue was dissected free of membranes, rinsed and minced in Ca2+-, 
Mg2+-free Hank's balanced salt solution. Cytotrophoblasts were isolated after trypsin-DNase 
digestion and discontinuous Percoll gradient fractionation, using a slight modification of the 
method of Kliman and Alsat. (10, 11) and was adapted for second-trimester placentas. The 
villous sample was submitted to sequential enzymatic digestions, in a solution which contains 
0.5% of powder trypsin (W/V, Difco), 5 IU/ml of DNAse I, 25 mM HEPES, 4.2 mM MgSO4 
and 1% (W/V) penicillin/ streptomycin (Biochemical Industry, Israel) in HBSS and 
monitored under light microscopy. The first and/or second digestion were discarded after 
light microscopy analysis in order to eliminate syncytiotrophoblast fragments and the 
following four or five sequential digestions were kept. The cells collected during these last 
digestions were purified on a discontinuous gradient of Percoll (5 to 70% in 5% step). The 
cells that migrated to the middle layer (density 1.048-1.062 g/ml) were plated on culture 
dishes (106 cells/cm2), attached to the dishes and 3 hours after plating were carefully washed 
by three washes with culture medium. Following this procedure, we checked that at 3 hours 
of culture, 90%-95% of the cells isolated from normal or T21 placentas were cytokeratin 7-
positive using a specific monoclonal antibody (dilution 1:200, Dako, France), less than 0.5% 
were vimentin- positive (dilution 1:200, Amersham International), and the other cells were 
mononucleated and identifed as macrophages. None of these cells were hPL-positive using a 
polyclonal specific antibody (dilution 1:500, Dako). 
Cells were plated in triplicate either on glass slides for immunocytochemistry or onto 60 mm 
culture dishes (106 cells/cm2). They were cultured for 3 days as previously described (11). 
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Cell staining. To detect desmoplakin or E-cadherin, cytokeratin 7 or hPL, cultured cells were 
rinsed with PBS, fixed, and permeabilized in methanol at -20 °C, for 25 min. A monoclonal 
antidesmoplakin or E-cadherin antibody (1:400, Sigma, St Quentin Fallavier, France) or 
antihPL (1:500, Dako) or a  polyclonal anticytokeratin 7 (1:200, Dako) were then applied, 
followed by fluorescein isothiocyanate-labeled goat anti-mouse immunoglobulin (Sigma), as 
previously described (19). 
 
Immunoblotting. To detect hPL, cell extracts were prepared as previously described (19) and 
solubilized protein (5 µg) was immunoblotted using a rabbit polyclonal antibody against hPL 
(1:250, Dako, France) and the specific band was revealed by chemiluminescence (Pierce 
supersignal, Interchim France) after incubation with an anti-rabbit peroxidase-coupled 
antibody (19). 
 
Hormone assay. hCG concentration was determined in culture media by an enzyme-linked 
fluorescence assay (Vidas System, BioMerieux, Marcy l’Etoile, France). Assay sensitivity 
was 2 mU/ml. hPL concentration was assayed (Amerlex IRMA, Amersham) in maternal 
serum and in four-fold concentrated conditioned media. Assay sensitivity was 0.5 µg/ml. 
Leptin was determined in four-fold concentrated conditioned media using the Sensitive 
Human Leptin RIA kit (Linco, St Louis USA). Assay sensitivity was 0.05 ng/ml. All values 
are means ± SEM of triplicate determinations. 
 
Protein determination. Protein was determined according to Bradford’s method (BioRad kit, 
France) using bovine serum albumin as standard. 
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Statistical tests. Statistical analysis was performed using the StatView F-4.5 software 
package (Abacus Concepts, Inc., Berkeley, CA, USA). Values are presented as mean ± SEM. 
Significant differences were identified using Mann-Whitney analysis for hormonal secretions 
and ANOVA for transfections; p < 0.05 was considered significant. 
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RESULTS 
 
In vitro  morphological cytotrophoblast differentiation in Trisomy 21 
Isolated cytotrophoblasts from normal placenta aggregate and fuse in vitro within 48 to 72 
hours to form a syncytiotrophoblast  (10, 11, 13). This is indicated by a gathering of nuclei in 
a large cytoplasmic mass. In the present study, these results were confirmed in 10 different 
primary cultures of cytotrophoblasts isolated from 10 normal placentas. 
In contrast, cytotrophoblasts isolated from 15 different T21-affected placentas had the same 
plating efficiency as controls, aggregated, but did not fuse or fused poorly. After three days of 
culture, syncytiotrophoblasts were rare as indicated by immunodetection of desmoplakin (a 
desmosomal plaque protein) (Fig 1) and of E-cadherin (a cell adhesion molecule) (data not 
shown). Indeed, desmoplakin and E-cadherin were absent from normal syncytiotrophoblasts 
as previously shown (19), but present at intercellular boundaries in cultured cells isolated 
from T21-affected placentas. This illustrates a decrease and/or delay in syncytial formation in 
T21. 
Failure of functional differentiation of cultured cytotrophoblasts in Trisomy 21 
In cells isolated from normal placenta, in vitro syncytiotrophoblast formation was associated 
with large increases in hCGα mRNA, hCGβ mRNA (Fig. 2), hPL mRNA (Fig.3), leptin 
mRNA and PGH mRNA (Fig 4). Concomitantly, hCG (Fig.2), hPL (Fig.3) and leptin (Fig.4) 
secretion in culture medium increased with time. In cells isolated from T21-affected 
placentas, the defect in syncytiotrophoblast formation was associated with a clear decrease in 
hCGα, hCGβ mRNA and hCG secretion in culture medium (Fig.2), as compared to normal 
cells. Human PL, leptin and PGH mRNA levels were very low. Human PL and leptin 
secretion could not be detected in culture medium after 3 days. Intracellular hPL was not 
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detected in T21-affected cells in contrast to normal cells. Because glucose inhibits secretion 
of placental GH (24), this hormone was not assayed in culture medium. 
These results suggest that the defect and/or delay in morphological differentiation into 
syncytiotrophoblast of cytotrophoblasts isolated from T21-placenta, was associated with a 
decrease in both expression and secretion of hormones specifically synthesized in the 
syncytiotrophoblast. 
mRNA expression of syncytiotrophoblast hormonal markers in normal and T21-
affected placentas. 
In order to confirm these in vitro data, we compared in total homogenates of  eight T21-
affected placentas and eight gestational age-matched controls (12-35 weeks)  transcript levels 
of these hormones specifically expressed in the syncytiotrophoblast. As shown in Figure 5, 
although levels of the five transcripts varied greatly from one normal placenta to another, the 
expression of these five genes was significantly lower in T21-affected placenta. Placental 
samples were homogeneous since no significant differences versus controls were noted in 
cytokeratin 7 mRNA (specifically expressed in the epithelial component of the chorionic villi, 
ie the cytosyncytiotrophoblast), in pleiotropin  (trophoblastic growth factor) or in β2 
microglobulin levels (ubiquitous gene) (Fig.6). 
These results suggest a decrease in functional syncytiotrophoblast mass in T21-affected 
placenta. 
 
Human placental lactogen levels in maternal circulation in T21-affected pregnancy. 
During pregnancy, massive amounts of hPL are synthesized by the syncytiotrophoblast and 
secreted directly into the maternal circulation (8). We therefore checked whether the defect in 
functional syncytiotrophoblasts in T21- affected placentas was associated with a decreased 
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level of hPL in the maternal circulation. As shown in Figure 7, we confirmed that hPL levels 
were lower in pregnancies with fetal T21 from 14 to 26 weeks of gestation. 
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DISCUSSION 
 
 The human placenta is hemomonochorial and is specific in its structure and endocrine 
functions. One of its major components is the syncytiotrophoblast, at the surface of the 
chorionic villi,which bathes directly in the maternal blood and arrives in the intervillous space 
through the uterine spiral arteries. The highly polarized syncytiotrophoblast secretes its 
hormonal products into the maternal circulation with almost no storage capacity. Any 
alteration in syncytiotrophoblast formation and/or function should therefore be reflected in 
the maternal circulation by changes in the levels of syncytiotrophoblast-secreted hormones. 
  In the present study, we checked that the fetus and placenta were both T21-affected. 
Cytotrophoblasts isolated from normal and T21-affected placentas were cultured. We 
confirmed that in vitro normal cytotrophoblasts aggregate and fuse to form the 
syncytiotrophoblast (10, 11). This syncytiotrophoblast formation was associated with an 
increased secretion in culture medium of hCG (7), hPL (8), PGH (9) and leptin (25) as 
previously shown. We demonstrate in this study that transcript levels of these hormones also 
increased with cytotrophoblast differentiation. In trisomy 21, cytotrophoblasts adhered to 
culture dishes, aggregated but did not fuse (or fused poorly), as observed by light microscopy, 
confirming the preliminary observations of Eldar-Geva et al. (26), and as demonstrated here 
by the expression of E-cadherin and desmoplakin. These results are in agreement with 
previous macroscopic and histological observations of T21-affected placentas which reveal 
delayed maturation of chorionic villi and syncytiotrophoblastic hypoplasia with a resistant 
cytotrophoblastic layer in the third trimester (27, 28).  
This decrease in the syncytiotrophoblast functional mass in T21 placentas is further suggested 
by the results obtained in homogenates of placental tissues. Indeed, we measured 
concomitantly by real-time quantitative RT-PCR the expression of the five hormonal genes 
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specifically expressed in the syncytiotrophoblast and encoding hormones secreted in the 
maternal circulation. In normal placenta, a large variation in mRNA expression of 
syncytiotrophoblast hormones was observed, despite the fact that our sampling was 
homogeneous as confirmed by cytokeratin 7, pleiotropin and ß2-microglobulin expression 
levels. Despite these variations, mRNA expression of hormones (hCGß, hCGα, hPL, PGH, 
leptin) specifically expressed in the syncytiotrophoblast decreased significantly in T21-
affected placentas. 
 In this study, we have demonstrated for the first time that in T21-affected placenta there 
is a defect and/or delay in the formation of the syncytiotrophoblast associated with a decrease 
in hPL, hCG, PGH and leptin expression and production. These results do not agree with the 
previous study of Eldar-Geva (26) reporting an increase in hCGα and hCGβ mRNA in 
trophoblast cells of T21-affected placenta. This discrepancy may be explained  by two facts: 
1) Eldar-Geva’s study was based on the comparison of one normal and one T21-affected 
placenta which were not gestational age-matched; 2) the cytotrophoblasts in culture may have 
been contaminated by fragments of syncytiotrophoblast (29) as hCG secretion diminished 
instead of increased with time in culture. It is crucial to monitor carefully the isolation and 
purification of cytotrophoblasts in order to avoid contamination by syncytiotrophoblast 
fragments. Our method including sequential enzymatic digestion, Percoll gradient 
purification and careful washing of the cells attached to the dish circumvents this problem. 
Failure to immunodetect hPl in the plated isolated cells unambiguously excludes 
contamination by syncytiotrophoblast fragments. 
 As anticipated by the results of our in vitro  studies, we demonstrated low maternal 
serum hPL levels in T21-affected pregnancies. Changes in hPL level during gestation showed 
that the difference between controls and T21-affected pregnancies was not significant 
between 15 and 18 weeks. This difference became clearer at 19 weeks and increased up to 24 
H
AL author m
anuscript    inserm
-00128454, version 1
 13 
weeks. This trend paralleled the increase in syncytiotrophoblast mass. These results explain 
why Ryall et al. observed no differences in maternal serum hPL between 15 and 18 weeks in 
48 cases of trisomy 21 (30). In contrast to the results of our in vitro studies, maternal hCG 
levels are elevated in T21-affected pregnancies (5, 6, 31). Our study demonstrates a decrease 
in the synthesis and secretion of hCG in cultured cells from ten T21-affected placentas as 
well as a decrease in hCG transcripts in eight total placenta extracts in Trisomy 21. How can 
we explain this paradox?  Maternal levels of hormones of syncytiotrophoblastic origin can be 
related to transcription but also to the post-translational process, which may modify hormonal 
stability. hCG is a complex of two glycosylated subunits. In Trisomy 21, hCG may be subject 
to post-transcriptional changes as suggested by Brizot et al. (32, 33) and recently confirmed 
by reports of a hyperglycosylated form of hCG in Down syndrome (34, 35). This 
hyperglycosylated form may have a different half-life, thus explaining elevated maternal 
levels. In contrast,  hPL  is not glycosylated and the decrease in its synthesis and secretion 
was directly reflected by a decreased level in the maternal serum after 19 weeks of gestation. 
 In conclusion, we have demonstrated that: 1) there is an abnormal formation of the 
syncytiotrophoblast in Down syndrome; 2) there is therefore a decrease in production of 
pregnancy-specific polypeptide hormones by the placenta in Down syndrome. This finding 
will enhance understanding of the maternal hormonal changes of placental origin that are 
used as markers of fetal Down syndrome and will be of help in finding new markers of 
placental origin. The syncytiotrophoblast plays a key functional role during pregnancy. Better 
knowledge of its alterations in T21 may therefore be useful in understanding some aspects of 
fetal development in Down syndrome. 
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LEGENDS 
 
Table I: Clinical histories of each control (panel A) and T21-affected (panel B) case. TOP: 
Termination of pregnancy; AVC: Atrioventricular communication; IVC: Interventricular 
communication. 
Table II: Characteristics of the PCR assays used in this study.  
Figure 1: Desmoplakin immunodetection after three days of culture of trophoblast cells 
isolated from normal placenta (A) and trisomy 21-affected placenta (B). Positive 
immunofluorescence staining is only observed in cytotrophoblasts that are in contact with the 
syncytiotrophoblast; staining has disappeared in the fused syncytiotrophoblast. In cells 
isolated from trisomy 21-affected placenta, desmoplakin staining is observed at the 
boundaries between aggregated cytotrophoblasts (X 2200). 
 
Figure 2: Panel A hCGα mRNA and hCGβ mRNA expression during differentiation of 
cytotrophoblasts isolated from normal (N) and trisomy 21-affected placentas (T21) and 
cultured for three days. mRNA data are expressed as the level of each marker mRNA 
normalized by PPIA (Peptidylprolyl isomerase A also called cyclophilin A, a housekeeping 
gene product)  mRNA.Three culture dishes were pooled for each determination. hCG 
transcript levels were assayed in duplicate. 
hCG secretion in the culture medium expressed in mIU/ml. The results are expressed as the 
mean ± SEM of these 3 culture dishes. ***: p ≤0.001 
The results are from one representative experiment. 
Panel B Mean hCG secretion in the culture medium of 8 primary cultures of 8 control 
placentas (N) and 10 primary cultures from 10 trisomy 21-affected placentas (T21). The 
results are expressed as the mean ± SEM of 3 culture dishes at each time in culture. 
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Figure 3: hPL expression, secretion in the culture medium and intracellular levels during 
differentiation of cytotrophoblasts isolated from normal (N) and trisomy 21-affected 
placentas (T21) and cultured for three days. 
Upper panel: levels of hPL transcripts. Data are expressed as the levels of hPL mRNA 
normalized by PPIA  mRNA. 
Middle panel: hPL secretion in the culture medium, expressed in µg/ml. The results are 
expressed as the mean ± SEM of these 3 culture dishes. ND: not detected. 
 
Lower panel: intracellular hPL levels as detected by Western blotting using a specific 
monoclonal antibody. 
The figure shows the same experiment as in figure 2. 
 
Figure 4: Leptin expression and secretion, PGH expression during differentiation of 
cytotrophoblasts isolated from normal (N) and trisomy 21-affected placentas (T21) and 
cultured for three days.. 
Upper panel: levels of leptin transcripts. Data are expressed as the level of leptin mRNA 
normalized by PPIA mRNA. 
Middle panel: leptin secretion in the culture medium, expressed in ng/ml. 
Lower panel: levels of PGH transcripts. Data are expressed as the level of PGH mRNA 
normalized by PPIA mRNA. 
The figure shows the same experiment as in figure 2. 
 
Figure 5: Expression of hPL, hCGα, hCGβ, PGH and leptin transcripts in normal placentas 
(N) and in trisomy 21-affected placentas (T 21). Data are expressed as ratios of each marker 
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transcript level per PPIA (mean ± SEM). The 8 normal and gestational age-matched trisomy 
21 samples are numbered from 1 to 8 for the purposes of comparison. Number 1: 12 weeks of 
gestation (wks), 2: 14 wks, 3: 16 wks, 4: 18 wks, 5:20 wks, 6: 23 wks, 7: 25 wks, 8: 35 wks. 
The p value indicates a significant difference between normal and trisomy 21-affected 
placentas. 
 
Figure 6: Expression of cytokeratin 7, pleiotropin and β2 microglobulin transcripts in these 
same 8 normal placentas (N) and in 8 trisomy 21-affected placentas (T 21). Data are 
expressed as ratios of each marker transcript level per PPIA transcript (mean ± SEM). The 8 
normal and gestational age-matched trisomy 21 samples are numbered from 1 to 8 for the 
purposes of comparison. NS indicates a non-significant difference between normal and 
trisomy 21-affected placentas. 
 
Figure 7: Maternal serum hPL levels (median) during normal pregnancies (0) and T21-
affected pregnancies (). The number of individual assays for each gestational stage is 
indicated next to each point. ***: p <0.001. 
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ID 
 
Maternal 
age 
 
Ultrasound 
findings 
 
Karyotype 
 
Gestational 
age at TOP 
 
Anatomical findings 
 
1 
 
25 
 
normal 
 
46XX 
 
12 
 
- 
 
2 
 
31 
 
normal 
 
46XX 
 
14 
 
- 
 
3 
 
30 
 
skeletal abnormalities 
 
46XX 
 
16 
 
dwarfism 
 
4 
 
32 
 
hygroma 
 
46XX 
 
18 
 
polymalformation 
 
5 
 
28 
 
polycystic kidney 
 
46XY 
 
19 
 
polycystic kidney 
 
6 
 
25 
 
polycystic dysplasia 
 
46XY 
 
20 
 
polycystic kidney 
 
7 
 
24 
 
polycystic dysplasia 
 
46XY 
 
20 
 
polycystic kidney 
 
8 
 
24 
 
polymalformation 
 
46XY 
 
23 
 
polycystic kidney 
 
9 
 
24 
 
polymalformation 
 
46XY 
 
25 
 
skeletal abnormalities 
 
10 
 
27 
 
interventricular communication 
 
46XX 
 
35 
 
cardiomyopathy 
       Panel A 
 
 ID 
 
Maternal 
age 
 
Ultrasound 
findings 
 
Karyotype 
 
Gestational 
age at TOP 
 
Anatomical findings 
1 39 abnormal nuchal 
translucency 
47XY 12 facial dysmorphy 
2 40 abnormal nuchal 
translucency 
47XY 13 facial dysmorphy 
3 37 hygroma 47XX 14 AVC 
4 41 normal 47XY 15 IVC 
5 26 abnormal nuchal 
translucency 
47XX 16 AVC 
6 32 abnormal nuchal 
translucency 
47XX 18 facial dysmorphy 
7 43 normal 47XY 19 facial dysmorphy 
8 41 normal 47XX 20 renal malformation 
9 42 normal 47XX 20 facial dysmorphy 
renal malformation 
10 43 normal 47XY 23 facial dysmorphy 
renal malformation 
11 33 normal 47XY 23 facial dysmorphy 
12 34 IVC 47XY 24 facial dysmorphy 
AVC 
13 49 normal 47XX 25 facial dysmorphy 
renal malformation 
    Panel B 
 
 
 
 
genes 
 
primers and probes 
 GenBank accession 
number 
 
proteins 
 
CGA 
(+) TCCCACTCCACTAAGGTCCAA 
(-) CCCCATTACTGTGACCCTGTT 
FAM-CACAGCAAGTGGACTCTGAGGTGACG-TAMRA 
 
106 bp 
 
V00518 
 
hCGα 
 
CGB 
(+) GCTACTGCCCCACCATGACC 
(-) ATGGACTCGAAGCGCACATC 
FAM-CCTGCCTCAGGTGGTGTGCAACTACC-TAMRA 
 
94 bp 
 
J00117 
 
hCGβ 
 
CSA 
(+) GCATGACTCCCAGACCTCCTT 
(-) TGCGGAGCAGCTCTAGATTGG 
FAM-TTTCTGTTGCGTTTCCTCCATGTTGG-TAMRA 
 
157 bp 
 
J03071 
 
hPL 
 
GHV 
(+) AGAACCCCCAGACCTCCCT 
(-) TGCGGAGCAGCTCTAGGTTAG 
FAM-TTTCTGCTGCGTTTTCACCCTGTTG-TAMRA 
 
96 bp 
 
J03071 
 
PGH 
 
LEPTIN 
(+) ACATTTCACACACGCAGTCAGT 
(-) CCATCTTGGATAAGGTCAGGAT 
FAM-TGGAGCCCAGGAATGAAGTCCAAA-TAMRA  
 
96 bp 
 
U18915 
 
leptin 
 
KRT7 
(+) GGACATCGAGATCGCCACCT 
(-) ACCGCCACTGCTACTGCCA 
FAM-TCACGGCTCCCACTCCATCTC-TAMRA 
 
171 bp 
 
X03212 
 
cytokeratin 7 
 
PTN 
(+) GAGATGTAAGATCCCCTGCAACT 
(-) CTCGCTTCAGACTTCCAGTTCT 
FAM-AGCAATTTGGCGCGGAGTGCAA-TAMRA 
 
125 bp 
 
M57399 
 
pleiotropin 
 
B2M 
(+) ACCCCCACTGAAAAAGATGAGT 
(-) GGCATCTTCAAACCTCCATGA 
FAM-AGTCACATGGTTCACACGGCAGGCA-TAMRA 
 
117 bp 
 
M17986 
 
β2 microglobulin 
 
PPIA 
(+) GTCAACCCCACCGTGTTCTT 
(-) CTGCTGTCTTTGGGACCTTGT 
FAM-AGCTCAAAGGAGACGCGGCCCA-TAMRA 
 
97 bp 
 
Y00052 
 
cyclophilin A 
 
SOD-1 
(+) CTGAAGGCCTGCATGGATTC 
(-) CCAAGTCTCCAACATGCCTCTC 
 FAM- TCATCCTTTGGCCCACCGTGTTT -TAMRA 
 
138 pb 
 
X02317 
 
CuZn superoxide 
dismutase 
 
 0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
5 0 0 0
N T 21
hCG!
2
8
7
4 , 6
5
1 , 3
0
5 0 0 0
10000
15000
20000
25000
N T 21
hPL
1
7
6
5 , 4
3
8
2
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
N T 21
hCG"
1
7
4
5 , 8
2
6
3
0
3 0 0
6 0 0
9 0 0
1 2 0 0
1 5 0 0
N T 21
PGH
1
7
2
4
6
5
3
8
0
1 0 0
2 0 0
3 0 0
4 0 0
N T 21
 Leptin
2
8
6
5 , 1
7 , 4
3
 
 
 
 
 
 
hPL 
 
hCGα 
 
hCGβ 
 
PGH 
 
Leptin 
 
 
 
N 
 
 
T 21 
 
 
N 
 
 
T 21 
 
N 
 
 
T 21 
 
 
N 
 
 
T 21 
 
 
N 
 
 
T 21 
 
mean 7424 503 3401 567 1012 59 386 36 68 9.5 
SEM 
 
±7606 ±400 
 
±2294 ±710 ±1463 ±63 ±377 ±30 ±99 ±15 
 
 
p 
 
0.0087 
 
0.0087 
 
0.0063 
 
0.0016 
 
0.0116 
